Fruitful summer for pharma expected
Experts are predicting a boost to European pharmaceutical and biotech market revenue later this summer, following an important decision from the Enlarged Board of...
Sanofi-Aventis pledges flu vaccines
Sanofi-Aventis will donate 100 million doses of influenza vaccine to the World Health Organization (WHO) to help people in developing countries, the company has...
Innovation fund for life sciences
The life sciences industry has welcomed Lord Mandelson’s announcement of the creation of an Innovation Fund which will be corner-stoned by Government with investment...
EU recommendation for once-daily Mirapexin
The CHMP of the European Medicines Agency (EMEA) has recommended the approval of a once-daily formulation for Mirapexin/Sifrol (pramipexole) throughout the EU. The...
New treatments urgently needed, says bone cancer trust
The Bone Cancer Research Trust (BCRT) is calling for new treatments for bone cancers affecting children and young people including osteosarcoma and Ewing's sarcoma,...
Initial EU approval for Onglyza
Onglyza (saxagliptin) has received a CHMP positive opinion as add-on therapy to improve glycaemic control in adult patients with type 2 diabetes. The...
Roche ‘walks away’ from ABPI
Roche has decided not to review its membership of the ABPI in a controversial move that has led analysts to question the effectiveness of...
J&J and Elan form Alzheimer’s agreement
Johnson & Johnson is to acquire the Elan Corporation’s Alzheimer's Immunotherapy Program (AIP Program), through a newly-formed company. As part of the...
HRA Pharma establishes UK presence
HRA Pharma has established a UK subsidiary, HRA Pharma UK Ltd, based in London. This is the company’s second subsidiary in Europe as...
First pediatric PAH therapy approved in EU
Actelion’s pediatric dispersible formulation of Tracleer (bosentan) for the treatment of pulmonary arterial hypertension (PAH) has been approved in the EU. The approval...